Steve Kubby at Cannabis Science - Steve Kubby (President and CEO) and Richard Cowan (Directory and Chief Financial Officer) have teamed up to create Cannabis Science, a company devoted to research and development of cannabis-based pharmaceuticals. In this press release, they claim that their cannabis lozenges may be useful in treatment of swine and bird flu.
- SAN FRANCISCO--(BUSINESS WIRE)--Cannabis Science Inc. (OTCBB: GFON.OB), an emerging pharmaceutical cannabis company, reported today on the current state of development of its whole-cannabis lozenge in response to Homeland Security Administration Secretary Janet Napolitano’s declaration of a public health emergency to deal with the emerging Swine Flu pandemic. The Company’s non-toxic lozenge has properties that could alleviate many of the symptoms and harmful effects of the H5N1 bird flu and H1N1 swine flu viruses, and has offered its assistance to HSA today in a letter to Secretary Napolitano. The Company has offered to produce up to 1 million doses of its whole-cannabis lozenge, and provide them to HSA for distribution at cost.
- Cannabis Science Inc., President & CEO, Steven W. Kubby said, "We have the science and preliminary anecdotal results confirming the anti-inflammatory properties of our new lozenges and indicating they may present an effective and non-toxic treatment for minimizing the symptoms and harm from influenza infections. Our lozenges appear to down-regulate the body's excessive inflammatory response to the influenza virus, which could reduce the deadly consequences of an infection into something that is more like a common cold. Because of my cancer and diminished auto-immune functions, even common influenza is a deadly threat, and I’ve had incredible symptomatic relief with the lozenge.”